
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Hldgs is a promising biomedical company due to their accelerated technology, risk-reward sharing partnerships with medical device companies, and promising product candidates such as AVIM Therapy and Virtue SAB for the treatment of hypertension and atherosclerosis. The company has a strong financial outlook with significant cash reserves, expected revenue from partnerships and acquisitions, and accelerating enrollment in their clinical trials. While there is limited human clinical data at this time, the company's roadmap to FDA approval and potential commercial milestones make it a buy with a 12-month price target of $20.
Bears say
Orchestra BioMed Hldgs is facing a number of risks and uncertainties that could potentially impact its financial performance and ability to bring its product candidates to market. These include commercialization risk, competition from larger companies, limited human clinical data, dependence on external financing, and potential failure of intellectual property protection. While there are potential opportunities for the company, such as an expanded target patient population and Breakthrough Device designation, it is important to consider the potential challenges and risks in the overall outlook for the stock.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares